Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China

被引：2
作者：
Wang, Bing [1 ,2 ]
Ma, Ruiqing [1 ]
Shi, Guanjun [1 ]
Fan, Xiwen [1 ]
Rao, Benqiang [2 ]
Xu, Hongbin [1 ]
机构：
[1] Aerosp Ctr Hosp, Dept Myxoma, Beijing 100049, Peoples R China
[2] Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Beijing 100038, Peoples R China
来源：
ORPHANET JOURNAL OF RARE DISEASES | 2024年 / 19卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Hyperthermic intraperitoneal chemotherapy; Incomplete cytoreduction; Pseudomyxoma peritonei; Survival; Progression-free survival; EPITHELIAL NEOPLASMS; SURGERY; ORIGIN; METASTASES;
D O I：
10.1186/s13023-023-02995-w
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
BackgroundTo explore the application value of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei (PMP).MethodsWe retrospectively analyzed the clinical data of 526 patients with incomplete cytoreduction for appendiceal PMP to discover its prognostic factors, and the therapeutic value of HIPEC.ResultsThe 5-year and 10-year overall survival rates of patients after cytoreductive surgery (CRS) treated with HIPEC were significantly higher than those without HIPEC (5y-OS: 58% vs. 48%, 10y-OS: 37% vs. 16%, P = 0.032). The median progression-free survival (PFS) following CRS was 20 months, with a 20% 3-year PFS. The median PFS following CRS + HIPEC was 33 months, with a 60% 3-year PFS (P = 0.000). Univariate analysis indicated that HIPEC, gender, completeness of cytoreduction (CCR) and pathological grade had statistical difference. Multivariate analysis showed that CRS without HIPEC and high pathological grade were independent risk factors for poor prognosis and rapid tumor progression.ConclusionsHIPEC may prolong the survival in patients with incomplete cytoreduction for low-grade appendiceal PMP. High pathological grade indicates poor survival and rapid tumor progression.
引用
收藏
页数：7
相关论文
共 33 条
[1]   Pseudomyxoma peritonei originating from urachus-case report and review of the literature [J].
Agrawal, A. K. ;
Bobinski, P. ;
Grzebieniak, Z. ;
Rudnicki, J. ;
Marek, G. ;
Kobielak, P. ;
Kazanowski, M. ;
Agrawal, S. ;
Halon, A. .
CURRENT ONCOLOGY, 2014, 21 (01) :E155-E165
[2]   Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours [J].
Ansari, N. ;
Chandrakumaran, K. ;
Dayal, S. ;
Mohamed, F. ;
Cecil, T. D. ;
Moran, B. J. .
EJSO, 2016, 42 (07) :1035-1041
[3]   Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei [J].
Benhaim, Leonor ;
Faron, Matthieu ;
Gelli, Maximiliano ;
Sourrouille, Isabelle ;
Honore, Charles ;
Delhorme, Jean-Baptiste ;
Elias, Dominique ;
Goere, Diane .
SURGICAL ONCOLOGY-OXFORD, 2019, 29 :78-83
[4]  
CARR NJ, 1995, CANCER-AM CANCER SOC, V75, P757, DOI 10.1002/1097-0142(19950201)75:3<757::AID-CNCR2820750303>3.0.CO
[5]  
2-F
[6]  
Carr NJ, 2002, ARCH PATHOL LAB MED, V126, P837
[7]  
Carr NJ, 2016, AM J SURG PATHOL, V40, P14, DOI 10.1097/PAS.0000000000000535
[8]   Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy [J].
Chua, Terence C. ;
Moran, Brendan J. ;
Sugarbaker, Paul H. ;
Levine, Edward A. ;
Glehen, Olivier ;
Gilly, Francois N. ;
Baratti, Dario ;
Deraco, Marcello ;
Elias, Dominique ;
Sardi, Armando ;
Liauw, Winston ;
Yan, Tristan D. ;
Barrios, Pedro ;
Gomez Portilla, Alberto ;
de Hingh, Ignace H. J. T. ;
Ceelen, Wim P. ;
Pelz, Joerg O. ;
Piso, Pompiliu ;
Gonzalez-Moreno, Santiago ;
Van der Speeten, Kurt ;
Morris, David L. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) :2449-2456
[9]  
Daniel D, 2004, Ann Surg, V240
[10]   Clinical presentation of the pseudomyxoma peritonei syndrome [J].
Esquivel, J ;
Sugarbaker, PH .
BRITISH JOURNAL OF SURGERY, 2000, 87 (10) :1414-1418
1234